NSE · ZYDUSLIFE.NS
Zydus Lifesciences Limited
₹1,245.50+₹61.10 (+5.16%)
Zydus Lifesciences Limited’s quoted price sits in the upper half of its reported 52-week range, 0.27% below the high.
Loading market information…
NSE · GLAXO.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 10:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
GlaxoSmithKline Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 19.61% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
GlaxoSmithKline Pharmaceuticals Limited’s forward annual dividend is ₹57.00 per share, paid annual. The forward yield is 2.27% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
GlaxoSmithKline Pharmaceuticals Limited’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of ₹16.50. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow GlaxoSmithKline Pharmaceuticals Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:51 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2025 |
|---|
| May 15, 2025 |
| ₹15.51 |
| ₹9.74B-2.05% vs estimate |
| Q3 2025 | Feb 14, 2025 | ₹12.80 | ₹9.49B+8.43% vs estimate |
|---|
| Q2 2025 | Oct 29, 2024 | ₹14.67 | ₹10.11B+20.75% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,245.50+₹61.10 (+5.16%)
Zydus Lifesciences Limited’s quoted price sits in the upper half of its reported 52-week range, 0.27% below the high.
₹1,352.00+₹7.00 (+0.52%)
Dr. Reddy's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 4.45% below the high.
₹1,378.90+₹20.90 (+1.54%)
Cipla Limited’s quoted price sits in the lower half of its reported 52-week range, 13.46% below the high.
₹1,681.40+₹21.50 (+1.3%)
Aurobindo Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 3.37% below the high.
₹2,011.00+₹21.10 (+1.06%)
Lupin Limited’s quoted price sits in the lower half of its reported 52-week range, 20.5% below the high.
₹2,298.70-₹40.30 (-1.72%)
Glenmark Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 9.41% below the high.
₹25,750.00-₹395.00 (-1.51%)
Abbott India Limited’s quoted price sits in the lower half of its reported 52-week range, 16.0% below the high.
₹1,929.60+₹3.40 (+0.18%)
Ipca Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 5.32% below the high.
